|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
AU2002234755A1
(en)
|
2001-02-26 |
2002-09-12 |
Pharma Pacific Pty Ltd |
Interferon-alpha induced gene
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
BRPI0812970A2
(pt)
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
|
EP2250201B1
(en)
|
2008-01-29 |
2014-04-30 |
Ludwig Institute for Cancer Research Ltd. |
Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
SG11201502796RA
(en)
|
2012-12-13 |
2015-05-28 |
Aduro Biotech Inc |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
EP2996472B1
(en)
|
2013-05-18 |
2019-03-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
CU24377B1
(es)
|
2013-05-18 |
2018-12-05 |
Aduro Biotech Inc |
Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
|
|
EP3152217B1
(en)
|
2014-06-04 |
2018-08-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Cyclic di-nucleotides as modulators of sting
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
|
DK3233882T3
(da)
|
2014-12-16 |
2020-01-27 |
Kayla Therapeutics |
Fluorinerede cykliske dinukleotider til cytokininduktion
|
|
EP3233191A1
(en)
|
2014-12-16 |
2017-10-25 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN108137641B
(zh)
|
2015-08-13 |
2022-04-01 |
默沙东公司 |
作为sting激动剂的环状双核苷酸化合物
|
|
KR20180066241A
(ko)
|
2015-10-28 |
2018-06-18 |
아두로 바이오테크, 인코포레이티드 |
“인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
|
|
JP6411676B2
(ja)
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Stingの調節因子としての環状プリンジヌクレオチド
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
SG10201900628RA
(en)
*
|
2016-04-07 |
2019-02-27 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
JP6636673B2
(ja)
|
2016-10-04 |
2020-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
STINGアゴニストとしてのベンゾ[b]チオフェン化合物
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
WO2018227023A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
MA49772A
(fr)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme |
Agonistes benzo[b]thiophène de sting pour le traitement du cancer
|
|
AU2018311965A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
|
|
EP3685166A2
(en)
|
2017-09-20 |
2020-07-29 |
Mersana Therapeutics, Inc. |
Compositions and methods for predicting response to napi2b-targeted therapy
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
CA3078309A1
(en)
*
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Methods for administering sting agonists
|
|
US11377440B2
(en)
*
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
CA3247730A1
(en)
|
2017-11-07 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
CN110016021B
(zh)
|
2018-01-08 |
2021-05-07 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
CN110016025B
(zh)
|
2018-01-08 |
2021-08-06 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
EP3802534B1
(en)
|
2018-05-25 |
2022-07-13 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
|
US20210353652A1
(en)
|
2018-06-04 |
2021-11-18 |
Trustees Of Tufts College |
Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
|
|
WO2019243825A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Small molecule modulators of human sting, conjugates and therapeutic applications
|
|
CN112351778B
(zh)
|
2018-06-28 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
稠合三环杂环类化合物及其治疗用途
|
|
WO2020010451A1
(en)
*
|
2018-07-10 |
2020-01-16 |
Trillium Therapeutics Inc. |
Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
|
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
AU2019326633B2
(en)
|
2018-08-24 |
2022-09-08 |
Adlai Nortye Biopharma Co., Ltd. |
High activity sting protein agonist
|
|
CA3110474C
(en)
|
2018-08-29 |
2024-04-23 |
Adlai Nortye Biopharma Co., Ltd. |
Highly active sting protein agonist compound
|
|
SG11202101980VA
(en)
|
2018-09-12 |
2021-03-30 |
Silverback Therapeutics Inc |
Methods and composition for the treatment of disease with immune stimulatory conjugates
|
|
CN110963997A
(zh)
|
2018-09-28 |
2020-04-07 |
四川科伦博泰生物医药股份有限公司 |
杂环酰胺类化合物、包含其的药物组合物及其制备方法和用途
|
|
WO2020115676A1
(en)
*
|
2018-12-06 |
2020-06-11 |
Glaxosmithkline Intellectual Property Development Limited |
Novel pharmaceutical formulation
|
|
WO2020132566A1
(en)
*
|
2018-12-21 |
2020-06-25 |
Nimbus Titan, Inc. |
Sting pyrazole agonists and uses thereof
|
|
WO2020132549A1
(en)
|
2018-12-21 |
2020-06-25 |
Nimbus Titan, Inc. |
Sting heterocycle agonists and uses thereof
|
|
WO2020132582A1
(en)
*
|
2018-12-21 |
2020-06-25 |
Nimbus Titan, Inc. |
Sting agonists and uses thereof
|
|
CN111393404B
(zh)
|
2019-01-02 |
2023-02-17 |
中国科学院上海药物研究所 |
一类苯并噻吩类化合物及其药物组合物及应用
|
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
CN111471056B
(zh)
|
2019-01-23 |
2021-07-02 |
成都先导药物开发股份有限公司 |
一种大环类免疫调节剂
|
|
KR102702618B1
(ko)
|
2019-01-31 |
2024-09-06 |
히트젠 주식회사 |
면역조절제
|
|
WO2020181050A1
(en)
|
2019-03-05 |
2020-09-10 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
KR20210146370A
(ko)
|
2019-03-28 |
2021-12-03 |
루핀 리미티드 |
Sting 효능제로서의 매크로사이클릭 화합물
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
JP2022529183A
(ja)
|
2019-04-17 |
2022-06-17 |
アヴィディア テクノロジーズ, インコーポレイテッド |
リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法
|
|
CN111848573B
(zh)
|
2019-04-30 |
2023-04-07 |
四川科伦博泰生物医药股份有限公司 |
苯并噻吩酰胺类化合物及其制备方法和用途
|
|
JP7531508B2
(ja)
|
2019-04-30 |
2024-08-09 |
シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド |
ベンゾチオフェン化合物、その調製方法およびその使用
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
WO2021000770A1
(zh)
|
2019-07-02 |
2021-01-07 |
凯复制药有限公司 |
可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
DK4004002T3
(da)
|
2019-07-22 |
2024-09-30 |
Lupin Ltd |
Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed
|
|
CN112300227B
(zh)
|
2019-07-25 |
2023-11-28 |
江西济民可信集团有限公司 |
杂环酰胺类化合物及其制备方法和应用
|
|
KR20220056176A
(ko)
|
2019-08-02 |
2022-05-04 |
메르사나 테라퓨틱스, 인코포레이티드 |
암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
CN113248475B
(zh)
|
2020-02-11 |
2023-03-17 |
中国科学院上海药物研究所 |
一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
|
|
CN116196435B
(zh)
|
2020-04-02 |
2025-12-02 |
梅尔莎纳医疗公司 |
包含sting激动剂的抗体药物缀合物
|
|
WO2022147532A1
(en)
|
2021-01-04 |
2022-07-07 |
Mersana Therapeutics, Inc. |
B7h4-targeted antibody-drug conjugates and methods of use thereof
|
|
CN112898286A
(zh)
|
2021-01-28 |
2021-06-04 |
中国药科大学 |
苯并噻吩类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
|